JP2023531725A - ジクアホソルを含む点眼組成物 - Google Patents

ジクアホソルを含む点眼組成物 Download PDF

Info

Publication number
JP2023531725A
JP2023531725A JP2022579971A JP2022579971A JP2023531725A JP 2023531725 A JP2023531725 A JP 2023531725A JP 2022579971 A JP2022579971 A JP 2022579971A JP 2022579971 A JP2022579971 A JP 2022579971A JP 2023531725 A JP2023531725 A JP 2023531725A
Authority
JP
Japan
Prior art keywords
composition
diquafosol
present
xanthan gum
polyvinyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531725A5 (enExample
Inventor
イ，ジュンヨブ
リュ，サンロク
ハン，ビョンヒョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taejoon Pharmaceutical Co Ltd
Original Assignee
Taejoon Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taejoon Pharmaceutical Co Ltd filed Critical Taejoon Pharmaceutical Co Ltd
Publication of JP2023531725A publication Critical patent/JP2023531725A/ja
Publication of JP2023531725A5 publication Critical patent/JP2023531725A5/ja
Priority to JP2026077192A priority Critical patent/JP2026116465A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022579971A 2020-06-23 2021-06-23 ジクアホソルを含む点眼組成物 Pending JP2023531725A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026077192A JP2026116465A (ja) 2020-06-23 2026-05-01 ジクアホソルを含む点眼組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0076573 2020-06-23
KR20200076573 2020-06-23
PCT/KR2021/007923 WO2021261931A1 (ko) 2020-06-23 2021-06-23 디쿠아포솔을 포함하는 점안 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026077192A Division JP2026116465A (ja) 2020-06-23 2026-05-01 ジクアホソルを含む点眼組成物

Publications (2)

Publication Number Publication Date
JP2023531725A true JP2023531725A (ja) 2023-07-25
JP2023531725A5 JP2023531725A5 (enExample) 2024-07-02

Family

ID=79178835

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022579971A Pending JP2023531725A (ja) 2020-06-23 2021-06-23 ジクアホソルを含む点眼組成物
JP2026077192A Pending JP2026116465A (ja) 2020-06-23 2026-05-01 ジクアホソルを含む点眼組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026077192A Pending JP2026116465A (ja) 2020-06-23 2026-05-01 ジクアホソルを含む点眼組成物

Country Status (4)

Country Link
JP (2) JP2023531725A (enExample)
KR (3) KR102365008B1 (enExample)
CN (1) CN115701986A (enExample)
WO (2) WO2021261931A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114191378A (zh) * 2021-11-23 2022-03-18 温州医科大学附属眼视光医院 一种地夸磷索缓释凝胶及其制备方法与应用
KR102689517B1 (ko) 2023-10-26 2024-07-29 강현희 반려동물용 인공눈물의 조성물
WO2026075334A1 (ko) * 2024-10-02 2026-04-09 주식회사 대웅테라퓨틱스 개선된 안정성 및 투약 편의성을 갖는 레바미피드를 포함하는 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080112317A (ko) * 2006-03-23 2008-12-24 센주 세이야꾸 가부시키가이샤 잔탄검 및 글루코스를 포함하는 안약 조성물
JP4948176B2 (ja) * 2004-09-28 2012-06-06 千寿製薬株式会社 キサンタンガムおよびアミノ酸を含有する眼科用組成物
KR20170086111A (ko) * 2014-11-25 2017-07-25 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
KR20180063381A (ko) * 2014-12-25 2018-06-11 산텐 세이야꾸 가부시키가이샤 수성 점안액

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2333742C2 (ru) * 2001-01-09 2008-09-20 Луи Йохан ВАГЕНАР Применение декспантенола в композиции для ухода за контактными линзами
DE602004023106D1 (de) * 2003-11-07 2009-10-22 Senju Pharma Co Pharmazeutische zusammensetzung mit prostaglandin
AU2013222801B2 (en) * 2012-02-24 2015-09-17 Bausch & Lomb Incorporated Ophthalmic compositions with alkoxylated natural waxes
WO2016195072A1 (ja) * 2015-06-05 2016-12-08 参天製薬株式会社 ソフトコンタクトレンズが装用されたドライアイ患者の眼に点眼されるように用いられることを特徴とするドライアイ治療剤
CN104983786B (zh) * 2015-07-14 2020-03-10 泊诺(天津)创新医药研究有限公司 一种聚乙烯醇组合物
CN106692048A (zh) * 2017-01-19 2017-05-24 蚌埠丰原医药科技发展有限公司 一种含有聚乙烯醇的单剂量滴眼液及其制备方法
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
CA3112278A1 (en) * 2018-09-21 2020-03-26 Ps Therapy Ltd. Artificial tear, contact lens and drug vehicle compositions and methods of use thereof
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4948176B2 (ja) * 2004-09-28 2012-06-06 千寿製薬株式会社 キサンタンガムおよびアミノ酸を含有する眼科用組成物
KR20080112317A (ko) * 2006-03-23 2008-12-24 센주 세이야꾸 가부시키가이샤 잔탄검 및 글루코스를 포함하는 안약 조성물
KR20170086111A (ko) * 2014-11-25 2017-07-25 알러간, 인코포레이티드 안정화된 오메가-3 안과용 조성물
KR20180063381A (ko) * 2014-12-25 2018-06-11 산텐 세이야꾸 가부시키가이샤 수성 점안액

Also Published As

Publication number Publication date
KR20210158310A (ko) 2021-12-30
WO2021261927A1 (ko) 2021-12-30
WO2021261931A1 (ko) 2021-12-30
KR20210158355A (ko) 2021-12-30
KR102365008B1 (ko) 2022-02-23
JP2026116465A (ja) 2026-07-09
KR20220025775A (ko) 2022-03-03
CN115701986A (zh) 2023-02-14

Similar Documents

Publication Publication Date Title
KR101809713B1 (ko) 방부제 없는 프로스타글란딘계 비점성 용액의 고분자 전달 시스템
JP7812807B2 (ja) ジクアホソルを含む点眼組成物
TWI544934B (zh) 含有氟喹諾酮抗生素藥物之經改良藥學組成物
JP7716996B2 (ja) 薬剤を含む水性組成物のｐＨを安定化させるための方法
KR20180008868A (ko) 고농도 올로파타딘 안과용 조성물
JP6603785B2 (ja) 水溶性高分子を含む水性液剤
KR20150084996A (ko) 수계 캡사이시노이드 제형 및 제조 방법 및 용도
CA2841969A1 (en) Fixed dose combination of bimatoprost and brimonidine
KR102365008B1 (ko) 디쿠아포솔을 포함하는 점안 조성물
JP2003206241A (ja) 眼科用剤
JP2023550393A (ja) セチリジン及びトコフェルソランを含む眼科用組成物
JP5681472B2 (ja) 眼科用組成物
US11433021B2 (en) Palonosetron for the treatment or prevention of nausea and vomiting
JP5434981B2 (ja) 点眼剤
JP6963651B2 (ja) エピナスチン又はその塩を含有する水性組成物
JP2019535713A (ja) 眼圧降下用点眼組成物
JP5013735B2 (ja) 眼粘膜適用製剤
JP4961671B2 (ja) 点眼剤
JP5627235B2 (ja) 眼科用組成物
JP7534129B2 (ja) 多成分配合点眼剤
CN119968200A (zh) 包含溴莫尼定的眼用组合物
WO2000043015A1 (fr) Gouttes ophtalmologiques
JP2004043516A (ja) 眼科用剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260106